| abstract |
The present invention relates to mammalian Dickkopf 3 (Dkk3) as a marker of renal interstitial fibrosis/tubular atrophy (IF/TA), assessing the extent of renal tissue damage and thereby the risk of progression of chronic kidney disease (CKD), and the effect of therapeutic interventions on the progression of IF/TA in CKD, as well as to related methods and uses. In particular, the present invention relates to Dkk3 monoclonal antibodies, as well as fragments, regions and derivatives thereof, and animproved method for diagnosing renal IF/TA, and progressive CKD using said antibodies. |